Antibody Production Market to Reach $58.35 Billion by 2031

Meticulous Research®-a leading global market research company, published a research report titled 'Antibody Production Market by Product [Bioreactors (Single Use, Reusable), Chromatography, Filtration, Cell Lines, Media, Buffers, Resins], Antibody [Monoclonal, Polyclonal], Source [Mice, Rabbit], Process [Downstream, Upstream] - Global Forecast to 2031.

Download Sample Report Here @ https://www.meticulousresearch.com/download-sample-report/cp_id=5769

According to this latest publication from Meticulous Research®, the antibody production market is expected to grow at a CAGR of 11.4% from 2024 to reach $58.35 billion by 2031. The growth of this market is driven by growing demand for targeted antibodies, increasing investments in R&D by pharma & biotech companies, high burden and growing prevalence of cancer and autoimmune diseases, increasing use of immunoassays, and advancements in bioprocessing technologies. However, the high cost of antibody production and stringent regulatory framework restrain the growth of this market.

Furthermore, growing applications of antibodies in clinical trials and medical research, significant opportunities from developing countries, and growing risk and prevalence of infectious diseases are expected to generate growth opportunities for the players operating in this market. However, the complex nature of monoclonal antibodies poses a challenge for market stakeholders for antibody production.

Browse in depth @ https://www.meticulousresearch.com/product/antibody-production-market-5769

Key Players

The key players operating in the antibody production market are Thermo Fisher Scientific Inc. (U.S.), Agilent Technologies, Inc. (U.S.), Merck KgaA (Germany), Eppendorf SE (Germany), Sartorius AG (Germany), Danaher Corporation (U.S.), Waters Corporation (U.S.), Shimadzu Corporation (Japan), Solaris Biotechnology Srl (Italy), Infors AG (Switzerland).

Antibody Production Market: Future Outlook

The global antibody production market is segmented by product (instruments [bioreactors {Reusable Bioreactors, single-use bioreactors}, Chromatography systems, filtration system, and other instruments], consumables {cell lines & media, buffers & reagents, chromatography columns & resins, and other consumables}), Antibody Type {monoclonal antibodies, polyclonal antibodies, and recombinant antibodies}, by source {mice, rabbit, and other sources}, by process {downstream and upstream }, end user {pharmaceutical & biotechnology companies, clinical research organizations & contract development & manufacturing organizations, and academic & research institutes} and geography. The study also evaluates industry competitors and analyzes the market at the regional and country levels.

Based on product, the antibody production market is segmented into instruments, consumables, and software. In 2024, the instruments segment is expected to account for the largest share of the market. The need for high volume production of antibodies and scale of the production for commercial use, the need for separation of purification and isolation of antibodies, and the growing need for mass production of antibodies for therapeutic applications are the major factors attributed to the large segment share.

Speck to our analyst @ https://www.meticulousresearch.com/speak-to-analyst/cp_id=5769

Based on antibody type, the antibody production market is segmented into monoclonal antibodies, polyclonal antibodies, antibody segments, and recombinant antibodies. The monoclonal antibodies segment is expected to grow at the highest CAGR during the forecast period. This growth can be attributed to the growing application of monoclonal antibodies for the treatment of diseases and disorders, the growing use of monoclonal antibodies for cancer treatment, and the increasing focus of pharma & biotech companies on the development of monoclonal antibody-based therapeutics.

Based on source, the antibody production market is segmented into mice, rabbit, and other sources. In 2024, the mice segment is expected to account for the largest share of the market. This large share is attributed to the ready availability, low cost, short production times for mouse antibodies, ease of mouse husbandry and as the genetic approaches to engineering antibodies through recombinant technologies are more established for mice.

Based on process, the antibody production market is segmented into upstream and downstream. In 2024, the downstream segment is expected to account for the largest share of the market. This large share can be attributed to the high preference for downstream processing as it is used for recovery and purification of biosynthetic products, including antibodies from natural sources such as animal or plant tissue or fermentation broth, including the recycling of salvageable components and the proper treatment and disposal of waste.

Based on end user, the antibody production market is segmented into pharmaceutical & biotechnology companies, clinical research organizations and contract development & manufacturing organizations, and other end users. The pharmaceutical & biotechnology companies' segment is expected to grow at the highest CAGR during the forecast period. The major factors attributed to this growth are the expansion of antibody manufacturing facilitates, increasing R&D investments by pharma & biotech companies, the growing prevalence of chronic and infectious diseases, and the need for the development of antibody-based therapeutics for these diseases. In addition to that, the initiatives by the pharma and biotech companies to launch antibody-based therapeutics are further expected to drive the segment growth. For instance, in 2022, Brii Biosciences Limited (China), a biotech company involved in developing therapies and TSB Therapeutics (Beijing) Co., Ltd. (China), launched amubarvimab/romlusevimab combination, a long-acting COVID-19 neutralizing antibody therapy in China.

Geographic Review

This research report analyzes major geographies and provides a comprehensive analysis of the antibody production market in North America (U.S. and Canada), Europe (Germany, France, U.K., Italy, Spain, and RoE), Asia-Pacific (Japan, China, India, and RoAPAC), Latin America (Brazil, Mexico, and RoLATAM), and the Middle East & Africa. North America is expected to dominate the antibody production market in 2024, followed by Europe and Asia-Pacific. Technological advancements in bioprocessing, the high number of industry-academia collaborations for research and development of antibodies, the high prevalence of chronic diseases, and the high demand for biologics are expected to support North America's largest share.

Request Free Research Report Sample @ https://www.meticulousresearch.com/request-sample-report/cp_id=5769

About Us:
Meticulous Research® was founded in 2010 and incorporated as Meticulous Market Research Pvt. Ltd. in 2013 as a private limited company under the Companies Act, 1956. Since its incorporation, the company has become the leading provider of premium market intelligence in North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa.

Contact Us:
Meticulous Market Research Pvt Ltd
Office No-202, 203,204,205,206
2nd Floor, Pushpak Business Hub,
Wakad, Pimpri-Chinchwad,
411057, India.
Phone: +9102066394988

This release was published on openPR.